INNOVATIVE FEDERAL STRATEGIES, LLC for CERUS CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R.9495/S.____ Department of Defense Appropriations Bill, 2027, Title VI, all provisions related to blood safety. H.R.9260/S.____ Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, 2027 - Title II, all provisions related to blood safety.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERYNN D HOOK | — |
| JOSHUA KEY New | Deputy COS / Scheduler, Rep. Kay Granger / District Director, Rep. Mayra Flores / Deputy District Director & Constituent Advocate, Rep. Mike Coffman |
| CARL KIME | — |
| JOSEPH MINGES | — |
| LETITIA WHITE | — |
Defense DEF
H.R.8800/S.4784 National Defense Authorization Act, 2027, Title XIV, all provisions related to blood safety.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERYNN D HOOK | — |
| JOSHUA KEY | — |
| CARL KIME | — |
| JOSEPH MINGES | — |
| LETITIA WHITE | — |
Health Issues HCR
Contacted officials regarding the Red Blood Cell Clinical Trial Program and blood safety issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERYNN D HOOK | — |
| JOSHUA KEY | — |
| CARL KIME | — |
| JOSEPH MINGES | — |
| LETITIA WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.